^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Merkel Cell Carcinoma

    Related cancers:
    19h
    Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) (clinicaltrials.gov)
    P1/2, N=2, Terminated, Ariceum Therapeutics GmbH | N=50 --> 2 | Trial completion date: Dec 2026 --> Dec 2025 | Recruiting --> Terminated | Trial primary completion date: Aug 2026 --> Dec 2025; Study terminated due to strategic business decisions.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Bavencio (avelumab) • Zynyz (retifanlimab-dlwr) • SOMther (lutetium-177 DOTA satoreotide)
    1d
    NeoMatryx: Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab (clinicaltrials.gov)
    P2, N=135, Not yet recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
    New P2 trial
    |
    Libtayo (cemiplimab-rwlc)
    9d
    Contemporary Management of Malignant Eyelid Tumours: Surgical and Immunotherapeutic Advances. (PubMed, Clin Exp Ophthalmol)
    Management algorithms are increasingly multidisciplinary, integrating ophthalmology, dermatology, oncology, pathology, and reconstructive surgery. Ongoing challenges include timely detection, management of adverse effects, and the risk of recurrence and metastasis, necessitating long-term surveillance and individualised care.
    Review • Journal
    |
    PD-1 (Programmed cell death 1)
    16d
    Challenging Subtypes and Mimics of Papillary Thyroid Carcinoma: Highlights from a 22nd International Congress of Cytology Slide Seminar (Case Reports). (PubMed, Acta Cytol)
    Columnar cell carcinoma (CCC-PTC) is a rare subtype of PTC that is characterized by hypercellularity and pseudostratification. Co-expression of TTF-1 and CDX-2 is a useful clue to its diagnosis.
    Journal
    |
    ER (Estrogen receptor) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • TTF1 (Transcription Termination Factor 1) • NKX2-1 (NK2 Homeobox 1) • CDX2 (Caudal Type Homeobox 2) • PAX8 (Paired box 8)
    21d
    Primary Cutaneous Ewing Sarcoma With Unusual Features: Potential Mimic of Merkel Cell Carcinoma. (PubMed, Am J Dermatopathol)
    It underscores that dot-like CK20 and Neurofilament staining are not entirely pathognomonic for MCC diagnosis. In the differential diagnosis of cutaneous round cell tumors, which includes metastases, melanoma, and several sarcoma types, the present case reveals the diagnostic challenges of cutaneous sarcomas and highlights the necessity of a multimodal approach for accurate diagnosis.
    Journal
    |
    EWSR1 (EWS RNA Binding Protein 1) • SOX10 (SRY-Box 10) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor) • CD99 (CD99 Molecule)
    23d
    MERCURY: Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery (clinicaltrials.gov)
    P2, N=36, Active, not recruiting, Gruppo Oncologico del Nord-Ovest | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cisplatin • carboplatin • etoposide IV • Zynyz (retifanlimab-dlwr)
    24d
    Merkel cell carcinoma immunotherapy: key questions in the era of immune checkpoint blockade. (PubMed, J Immunother Cancer)
    Finally, (6) which timing of ICI therapy, that is, the neoadjuvant, adjuvant or therapeutic setting, offers the optimal overall outcomes for patients with MCC? A number of recent studies provide initial, but unfortunately not yet definitive answers.
    Review • Journal • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    25d
    A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers (clinicaltrials.gov)
    P1/2, N=73, Terminated, Ocellaris Pharma, Inc. | Trial completion date: Sep 2026 --> Nov 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2026 --> Nov 2025; Business Decision
    Trial completion date • Trial termination • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    HER-2 negative • ALK fusion • ALK mutation • ROS1 fusion
    |
    Bavencio (avelumab) • OC-001
    27d
    MicroRNAs as Diagnostic and Prognostic Biomarkers in Melanoma and Non-Melanoma Skin Cancers: An Updated Review. (PubMed, Diagnostics (Basel))
    Overall, current evidence supports miRNAs as promising diagnostic, prognostic, and predictive biomarkers in cutaneous oncology. Standardized methodologies and large-scale validation remain essential for their integration into routine clinical practice.
    Review • Journal
    |
    BRAF (B-raf proto-oncogene) • MIR34A (MicroRNA 34a-5p) • MIR182 (MicroRNA 182) • MIR18A (MicroRNA 18a) • MIR31 (MicroRNA 31) • MIR375 (MicroRNA 375) • MIR128 (MicroRNA 128) • MIR145 (MicroRNA 145) • MIR181A1 (MicroRNA 181a-1) • MIR203A (MicroRNA 203a) • MIR205 (MicroRNA 205) • MIR383 (MicroRNA 383)
    |
    BRAF mutation
    30d
    1B-22-2: In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, University of Southern California | Recruiting --> Active, not recruiting | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2027
    Enrollment closed • Trial completion date • Trial primary completion date • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • CDX-1140 • Hiltonol (poly-ICLC) • Mobista (CDX-301)
    1m
    At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer (clinicaltrials.gov)
    P2, N=200, Recruiting, Mayo Clinic | Trial completion date: Dec 2025 --> Jan 2027 | Trial primary completion date: Dec 2025 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    1m
    Cytokeratin 20-Negative Merkel Cell Carcinoma: A Case Series and Discussion of Diagnostic Strategies. (PubMed, Case Rep Dermatol Med)
    Thyroid transcription factor 1 (TTF-1) was negative in all instances, supporting the diagnosis of MCC. This case series illustrates the diagnostic value and limitations of PanCK and TTF-1 staining in MCC in cases where CK20 is negative and discusses strategies for diagnosing this rare variant of MCC.
    Journal
    |
    NKX2-1 (NK2 Homeobox 1) • KRT20 (Keratin 20)